Lives and livelihoods depend on understanding Long-COVID

The RECOVER study is designed to help us understand why some people continue to feel sick after having COVID-19 and others don’t. It will also help identify what can be done to speed recovery and even prevent it. Today, doctors don’t know.

Lives and livelihoods depend on understanding Long-COVID

The RECOVER study is designed to help us understand why some people continue to feel sick after having COVID-19 and others don’t. It will also help identify what can be done to speed recovery and even prevent it. Today, doctors don’t know.

Learning faster, together

RECOVER is a national research initiative from the National Institutes of Health (NIH). The federal government recognizes the impact of COVID and has asked for an official set of rules to be created to evaluate the long-term symptoms people are reporting. 

Illinois is one of 30 study centers nationwide that will develop best practices for people with difficulty recovering from COVID.

Long-COVID is real

Long-COVID is a condition that occurs after getting COVID-19. About 10-30% of people who get COVID-19 do not fully recover. Some people experience symptoms that persist for weeks or months and may come and go. For others, some symptoms go away, and new ones appear. 

Progress takes all of us

The RECOVER study in Illinois is for adults who: 

R

Currently
have COVID

Currently enrolling
volunteers

R

Recently
had COVID

Within the last
3-4 weeks

Q

Have not
had COVID

Goals achieved!
No longer enrolling.

Q

Previously
had COVID

Goals achieved!
No longer enrolling.

Meet the ILLInet RECOVER team

Dr. Jonathan D. Klein

Study Chair
University of Illinois at Chicago

Dr. Jerry A Krishnan

Lead Principal Investigator
University of Illinois at Chicago

Community partners

ILLInet is a network that includes health systems and community-based organizations in Illinois. Together, our goal is to enroll a diverse group of 1,200 people into the RECOVER study. 

 

UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
Logo for Bright Star
UI Health at University of Illinois at Chicago
Logo for the Chicago Urban League
Logo for Illinois Unidos
Logo for OSF Healthcare
UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
Logo for the Chicago Urban League
UI Health at University of Illinois at Chicago

Community partners

ILLInet is a network that includes health systems and community-based organizations in Illinois. Together, our goal is to enroll a diverse group of 1,200 people into the RECOVER study. 

 

UI Health at University of Illinois at Chicago
Logo for OSF Healthcare
UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
Logo for the Chicago Urban League
UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
UI Health at University of Illinois at Chicago
Logo for Bright Star
UI Health at University of Illinois at Chicago
Logo for Illinois Unidos
Logo for the Chicago Urban League
UI Health at University of Illinois at Chicago

“I’ve been doing medical research for over 25 years. The RECOVER study is big! This is new, ambitious, and necessary because Long COVID is a problem.”

Dr. Jerry Krishnan

Previous COVID studies

Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19

March – Sep 2020

This study determined if a study drug called sarilumab could decrease the amount of time a person has COVID-19 symptoms. 

LEARN MORE →

Predictors of Severe COVID-19 Outcomes (PRESCO)

May – Aug 2020

This study sought to understand the process of developing acute respiratory distress syndrome (ARDS: a condition in which fluid collects in the lungs’ air sacs, depriving organs of oxygen) in patients with COVID-19. Understanding this process helped prioritize patients with a high risk of progression to ARDS or death for earlier and more aggressive intervention.

LEARN MORE →

ACTIV-4c: COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

2021 – present

ACTIV-4c is a study to learn more about preventing blood clots in COVID-19 patients, which appears to be higher than for patients who do not have COVID-19. The purpose of this study is to compare people who take a low-dose blood thinner after leaving the hospital with people who do not.

LEARN MORE →

Interested in joining?

 

How did you find out about us?